Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut) - Ferrarotto, Renata; Metcalf, Robert; Rodriguez, Cristina P.; Muzaffar, Jameel; Even, Caroline; Perez, Cesar Augusto; Van Herpen, Carla M.L.-; Oliva, Marc; Xia, Bing; Bowles, Daniel W.; Popovtzer, Aharon; Winquist, Eric; et al. (Journal of clinical oncology, 2022)